Seegene Inc operates in the Diagnostic substances sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Seegene Inc with three other
pharmaceutical manufacturers in Asia:
Getein Biotech Inc
sales of 488.58 million Chinese Renmimbi [US$72.14 million]
of which 99%
was In-vitro diagnostics),
Guangdong Hybribio Biotech Co Ltd
(479.09 million Chinese Renmimbi [US$70.74 million]
of which 97%
was Monitoring Instrument), and
Beijing Leadman Biochemistry Co Ltd
based in China
(575.98 million Chinese Renmimbi [US$85.04 million]
of which 100%
was Biological products industry).
Seegene Inc reported sales of 87.66 billion Korean Won (US$77.84 million)
December of 2017.
increase of 19.0%
versus 2016, when the company's sales were 73.69 billion Korean Won.
Sales at Seegene Inc have increased during each of the previous five years
(and since 2012, sales have increased a total of 70%).